Let The US Drug-Coated Balloon Battle Begin

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market CR Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

The US drug-coated balloon market is now competitive. Medtronic PLC announced on January 5 FDA approval of its IN.PACT Admiral paclitaxel-coated balloon for treating peripheral artery disease, primed for a match up with CR Bard Inc.'s first-to-market Lutonix 035.

Bard had an almost three-month head start in the US, launching Lutonix in October. But Medtronic is expected to quickly...

More from Archive

More from Medtech Insight